CCCA (Central Centrifugal Cicatricial Alopecia): Regrowth Reality & 2026 Evidence

What does a slowly expanding patch of thinning hair at the crown mean for a Black woman in her 30s, 40s, or 50s, and what can actually be done to stop it?

When hair loss begins at the vertex or crown of the scalp—often accompanied by itching, tenderness, burning, or tingling—and gradually spreads outward in a circular pattern, the most likely clinical diagnosis is central centrifugal cicatricial alopecia (CCCA). CCCA is the most common primary scarring alopecia in women of African descent.

The honest answer on regrowth is that CCCA destroys hair follicles and replaces them with fibrous scar tissue. Hair cannot return from follicles that have already scarred over. Therefore, the primary objective of treatment is to halt inflammatory progression before permanent destruction occurs. Partial regrowth is achievable only in areas where follicles are inflamed but not yet fully obliterated. Speed of diagnosis and immediate medical intervention are the single most critical determinants of long-term hair preservation.

Contrary to historical assumptions that attributed CCCA exclusively to chemical relaxers, hot combs, or tight protective styles, landmark genetic research published in the New England Journal of Medicine identified pathogenic variants in the PADI3 gene in 21% to 31% of affected patients. Chemical and mechanical hair care practices act as aggravating environmental stressors rather than the sole underlying cause. Furthermore, while clinicians historically screened CCCA patients for metabolic comorbidities, a May 2026 retrospective case-control study in the Journal of the American Academy of Dermatology found no statistically significant association between CCCA and type 2 diabetes or hypertension.

---

1. What Is CCCA, and How Does It Differ from Other Hair Loss?

Central centrifugal cicatricial alopecia is a primary lymphocytic scarring alopecia characterized by inflammation that targets the bulge region of the hair follicle—the location of follicular stem cells. As these stem cells are destroyed, the follicle undergoes irreversible fibrotic degeneration, resulting in permanent loss of the follicular ostia (the visible scalp pores).

CCCA predominantly affects women of African ancestry between the ages of 30 and 60, with a mean age of onset of 36 years. Prevalence estimates in this population vary by a factor of five depending on how the count was made, and it is worth knowing why before you interpret any single figure:

• 2% to 7% — the range compiled in StatPearls (NBK559187), drawn largely from community and population-sampling studies.
• Up to 5.6% — the approximate disease prevalence cited in the 2019 NEJM genetics paper.
• Nearly 15% — an estimate quoted by the American Academy of Dermatology in its own patient-facing communications, attributed to dermatologist Valerie Callender.

The higher figures generally come from dermatology-clinic populations, where women with scalp symptoms are over-represented by definition; the lower figures come from broader community sampling, which will miss early or undiagnosed disease. Neither is "the" answer. What every estimate agrees on is that CCCA is common enough in Black women that crown thinning should never be dismissed as ordinary female pattern loss without a proper scalp examination.

Diagnostic Trichoscopy and Differential Diagnosis

To the untrained eye, early CCCA is frequently misdiagnosed as female pattern hair loss or traction alopecia. However, trichoscopic examination and clinical distribution reveal distinct diagnostic markers:

Understanding these distinctions is vital. Readers seeking deeper technical details on non-scarring pattern loss can consult our detailed review of medical treatment for pattern hair loss, while those experiencing hairline recession specifically may refer to our analysis of frontal fibrosing alopecia and traction alopecia prevention.

The Scalp Biopsy Standard

Because CCCA carries the longest average time to diagnosis among all scarring alopecias (JAAD Int 2025, PMID 41561206), definitive histological confirmation is critical. Dermatologists perform two 4-mm punch biopsies taken from the active, inflamed margin of the alopecia patch (not the completely smooth center, which yields only end-stage scar tissue).

One biopsy specimen is sectioned vertically to evaluate the depth of inflammatory infiltration, while the second is sectioned horizontally to measure follicular density and architectonic destruction. The classic early histological hallmark of CCCA is premature desquamation of the inner root sheath (PDIRS), accompanied by a perifollicular lymphocytic infiltrate and concentric perifollicular fibroplasia.

---

2. The Regrowth Reality: What "Scarring Alopecia" Means for Your Hair

The fundamental biological question every patient asks is: Will my hair grow back?

To answer accurately, one must distinguish between the active inflammatory phase and the burnt-out fibrotic phase:

1. Active Inflammatory Phase: The scalp exhibits perifollicular erythema, scaling, hyperpigmentation, and symptoms such as pruritus or tenderness. Microscopic evaluation shows intact but inflamed hair follicles. At this stage, aggressive anti-inflammatory intervention can preserve the follicle and allow miniaturized or resting hairs to resume normal anagen growth.
2. Burnt-Out Fibrotic Phase: The scalp appears smooth, shiny, and pale, with complete loss of follicular ostia. Histology confirms that the follicular anatomy has been entirely replaced by dense collagenous tissue. At this stage, no medical treatment, laser, topical oil, or platelet-rich plasma can recreate a hair follicle.

CCCA Disease Progression & Regrowth Potential

[Early Stage]                [Active Inflammatory Stage]          [Burnt-Out Fibrotic Stage]
Perifollicular inflammation   ---> Follicle swelling & pain       ---> Complete follicular scarring
Ostia preserved               ---> Ostia narrowing (Halo)         ---> Loss of ostia (Smooth scalp)
Regrowth potential: HIGH      ---> Regrowth potential: PARTIAL    ---> Regrowth potential: ZERO (Permanent)

Because scarred follicles cannot be restored, treatment success in CCCA is clinically defined as:

• Complete resolution of scalp pain, itching, and burning.
• Stabilization of the alopecia borders (no further expansion over a 6- to 12-month evaluation window).
• Maintenance or slight density improvement in surrounding non-scarred zones.

---

3. Genetics vs. Hair Care: What Causes CCCA?

For decades, clinical literature posited that CCCA was primarily a mechanical and chemical injury resulting from hot combs, chemical relaxers, tight weaves, and heavy pomades. This led to widespread patient self-blame. However, modern genomic discovery has fundamentally altered this paradigm.

The PADI3 Genomic Breakthrough

In 2019, an international consortium published a groundbreaking study in the New England Journal of Medicine (Malki et al., PMID 30763140) demonstrating that CCCA has a strong genetic underpinning. Researchers identified heterozygous missense and splice-site variants in the PADI3 gene (which encodes peptidylarginine deiminase type III):

• Discovery Cohort: PADI3 variants were identified in 5 of 16 patients (31.25%).
• Replication Cohort: PADI3 variants were present in 9 of 42 patients (21.43%).
• Control Population: The prevalence of these variants was significantly higher in CCCA patients than in healthy controls (P=0.002 to 0.04 across subgroups).

PADI3 plays a crucial role in post-translational protein modification required for normal hair shaft formation and inner root sheath hardening. When PADI3 function is impaired, hair shaft structural integrity is compromised.

Subsequent research published in the Journal of Investigative Dermatology (Keller-Rosenthal et al., 2026, PMID 41242654) took the genetic case considerably further. Analyzing whole-exome sequences from 75 patients with clinically and histologically confirmed CCCA, the investigators identified nine pathogenic heterozygous variants in PADI3 itself — four of them previously unreported — and then found pathogenic variants in two additional genes, S100A3 and TCHH, which encode the major substrates that PADI3 acts on (S100 calcium-binding protein A3 and trichohyalin). Both proteins are critical to hair shaft integrity. Functionally, the S100A3 variant reduced citrullination by PADI3, while the TCHH variants disrupted the protein's intracellular localization and sharply reduced its expression.

The practical implication is that CCCA is not a one-gene disease but a disorder of an entire hair-shaft protein pathway — which is why the same hair care practice can devastate one woman's scalp and leave her sister's untouched.

Fibroproliferative Gene Expression

Furthermore, work led by Dr. Crystal Aguh at Johns Hopkins (JAAD 2018, PMID 29913259) established that CCCA lesions exhibit preferential expression of fibroproliferative genes. This links CCCA to other fibrotic conditions that disproportionately affect individuals of African descent, such as keloid scarring and uterine fibroids.

Practical Modification of Hair Care Practices

While traction and chemical processing do not cause CCCA in genetically unaffected tissue, they accelerate follicular destruction in hair that carries underlying structural vulnerabilities. Dermatologists recommend the following evidence-based hair care adjustments:

• Relaxer Frequency: Discontinue chemical relaxers entirely if possible. If continued, extend application intervals to at least 10–12 weeks, ensure protective base oils are applied to the scalp, and never apply relaxer to inflamed or painful scalp tissue.
• Tension Reduction: Avoid tight cornrows, heavy box braids, high-tension weaves, and tight ponytail styles that place mechanical strain on vertex follicles.
• Thermal Exposure: Eliminate direct hot-comb contact with the scalp. Limit blow-drying and flat-ironing to low heat settings with thermal protectants.
• Scalp Hygiene: Wash the scalp every 7 to 14 days using a gentle sulfate-free or anti-inflammatory shampoo to clear sebum, scalp debris, and topical medicaments without stripping moisture.

---

4. Step-by-Step Treatment Ladder for CCCA

Medical management of CCCA follows a staged anti-inflammatory protocol designed to halt follicular destruction and suppress fibrotic signaling.

                        [CCCA Treatment Ladder]

Tier 4: Advanced / Surgical Options
  ├── Off-Label Biologics / JAK Inhibitors (Baricitinib, Upadacitinib - Case Evidence)
  ├── Surgical Hair Transplantation (Strict Requirement: 12-24 Months Disease Quiescence)
  └── Scalp Micropigmentation (SMP Camouflage for Burnt-Out Scarring)

Tier 3: Secondary Anti-Inflammatory & Emerging Agents
  ├── Oral Hydroxychloroquine (200 mg BID for refractory inflammation)
  ├── Topical 10% Metformin Compounded Cream (Fibroproliferative targeting)
  └── Low-Level Light Therapy (LLLT - Off-label adjunctive cohort evidence)

Tier 2: Systemic Anti-Inflammatory Therapy
  ├── Oral Doxycycline (100 mg BID for 2-6 months; dual antibacterial/anti-collagenase)
  └── Oral Minoxidil (0.625-1.25 mg daily for non-scarred follicular stimulation)

Tier 1: First-Line Topical & Intralesional Therapy (First-Line Clinical Management)
  ├── High-Potency Topical Corticosteroids (Clobetasol propionate 0.05% foam/solution)
  ├── Intralesional Triamcinolone Acetonide (ILTAC 5-10 mg/mL every 4-6 weeks)
  └── Topical Minoxidil 5% (Foam preferred to avoid propylene glycol irritation)

First-Line Therapy: Topical & Intralesional Corticosteroids

• Intralesional Triamcinolone Acetonide (ILTAC): Administered as 5 to 10 mg/mL injections directly into active scalp margins, spaced 0.5 to 1.0 cm apart (0.05–0.1 mL per site). Injections are repeated every 4 to 6 weeks for 3 to 6 cycles until active inflammation and symptoms resolve.
• Topical Corticosteroids: High-potency corticosteroids (clobetasol propionate 0.05% foam or solution) applied once daily to active areas 5 days per week, with a 2-day holiday to minimize cutaneous atrophy.

Second-Line Therapy: Oral Tetracyclines & Minoxidil

• Oral Doxycycline: Prescribed at 100 mg twice daily for 2 to 6 months. In CCCA, doxycycline is utilized primarily for its potent anti-collagenase, anti-matrix metalloproteinase (MMP), and anti-inflammatory properties rather than an antimicrobial effect. Once disease quiescence is achieved, the dosage is tapered.
• Topical or Low-Dose Oral Minoxidil: Topical 5% foam or oral minoxidil (0.625 to 1.25 mg daily) helps maintain follicle size and extend anagen duration in surviving, non-scarred surrounding hairs.

Third-Line Therapy: Hydroxychloroquine & Compounded Metformin

• Oral Hydroxychloroquine: 200 mg twice daily for patients with persistent symptoms resistant to corticosteroids and tetracyclines. Requires baseline and periodic ophthalmologic screening for retinal toxicity.
• Topical 10% Metformin: Formulated by compounding pharmacies in a liposomal base, topical metformin targets AMP-activated protein kinase (AMPK) signaling to reduce fibroproliferative tissue remodeling.

Pregnancy, Lactation, and Reproductive Safety

Because CCCA primarily affects women during their reproductive years (mean onset age 36), systemic and topical medications must be carefully evaluated for pregnancy and lactation compatibility:

• Oral Tetracyclines (Doxycycline / Minocycline): Absolute contraindications during pregnancy (FDA Category D / Teratogenic) due to risks of permanent dental discoloration, enamel hypoplasia, and maternal hepatotoxicity. Women of childbearing potential must utilize effective contraception while on oral tetracyclines.
• Topical Corticosteroids (Clobetasol Propionate): Low-to-moderate potency topicals can be used cautiously on localized scalp areas; ultra-high-potency topicals (clobetasol) should be restricted in duration during pregnancy to avoid systemic absorption and potential fetal growth restriction.
• Topical & Oral Minoxidil: FDA Category C. Minoxidil is excreted in breast milk and is generally avoided during pregnancy and active breastfeeding.
• Intralesional Triamcinolone: Localized low-dose injections (ILTAC) are generally preferred over systemic oral steroids when active control is urgently required during pregnancy, but treatment decisions require joint dermatologic and obstetric consultation.

Symptom Management: Managing Scalp Pruritus and Trichodynia

Scalp pruritus (itching) and trichodynia (scalp pain/burning) reflect active perifollicular lymphocytic inflammation. Scratching causes mechanical trauma that further damages fragile follicular structures:

1. Topical Antipruritics: Compounded lotions containing pramoxine hydrochloride 1% or menthol 0.5% offer rapid symptomatic relief without corticosteroid-induced dermal atrophy.
2. Cold Compress Applications: Applying cool, damp compresses to active vertex patches for 10 to 15 minutes suppresses inflammatory histamine release and calms burning sensations.
3. Anti-Inflammatory Wash Protocols: Utilizing over-the-counter or prescription ketoconazole 2% shampoo twice weekly reduces scalp Malassezia yeast populations, mitigating coexisting seborrheic inflammation that exacerbates CCCA discomfort.

---

5. Is CCCA Really Linked to Type 2 Diabetes? What Changed in 2026

A major point of confusion on consumer medical websites involves the relationship between CCCA and metabolic disease.

The 2011 Population Study (Kyei et al.)

In 2011, epidemiological work by Kyei et al. (Archives of Dermatology, PMID 21482861) analyzed 326 African American women and reported a statistically significant association between CCCA and type 2 diabetes mellitus ($P = .01$), as well as bacterial scalp infections ($P = .045$) and high-tension hair styles ($P = .02$).

That finding did not stand alone for long. A follow-up study by Roche et al. (JAAD, 2021) reported a substantially stronger association (odds ratio 4.13, 95% CI 2.76–6.18), and Ali et al. (JAAD, 2022) reported greater CCCA severity among patients with type 2 diabetes ($P = .043$). On the strength of that accumulating literature, the American Academy of Dermatology's public treatment page lists "testing for type 2 diabetes and treating it" among the approaches dermatologists are exploring for CCCA — worth noting precisely, because it is framed as an area of active investigation rather than as an established screening mandate.

The Counter-Evidence, and the May 2026 Re-Evaluation

Larger and better-controlled studies have since pushed the other way. Leung et al. (JAAD, 2023) found no significant association with type 2 diabetes or hyperlipidemia in a comorbidity chart review, and in May 2026 a retrospective case-control study in the Journal of the American Academy of Dermatology by Ong, Li, Vu and Lipner (PMID 41547373) found no statistically significant association between CCCA and type 2 diabetes mellitus or hypertension.

Clinical Takeaway: The honest summary is that this association is contested and trending toward null, not settled in either direction. Two practical consequences follow. First, a CCCA diagnosis is not by itself a reason to be worked up for diabetes — but neither is the newer evidence a reason to skip the age- and risk-appropriate metabolic screening every adult should have. Second, if a clinician tells you your hair loss means you probably have diabetes, that overstates what the current literature supports. CCCA is best understood as a genetic and fibroinflammatory follicular disease; the metabolic question is a live research thread, not a diagnostic conclusion.

---

6. Emerging Therapies: Metformin, JAK Inhibitors, and Laser Devices

Because no drug currently holds an FDA-approved indication specifically for CCCA, clinical management relies entirely on off-label treatment. This is the single most important thing to understand about CCCA therapy, and almost no consumer page states it plainly: there has never been a randomized controlled trial of any treatment for CCCA. Every recommendation in the previous section — including first-line corticosteroids — rests on case reports, small series, single-center case-control studies, and expert consensus.

The nearest thing to a guideline is the 2024 Delphi consensus recommendations for CCCA treatment published in JAAD, in which an expert panel converged on management steps in the explicit absence of trial data. Consensus is a legitimate way to practice when trials do not exist, but it is expert opinion, and it should be weighted as such.

Against that backdrop, here is where each emerging option actually sits:

Evidence Quality Ladder for CCCA Therapies

[Tier 1: RCTs]           ---> NONE EXIST for any CCCA treatment
[Tier 2: Expert consensus]--> Delphi consensus recommendations (JAAD 2024)
[Tier 3: Cohort studies] ---> Low-Level Light Therapy (Larrondo 2026, interventional cohort)
[Tier 4: Case series]    ---> Topical 10% Metformin Cream (Araoye 2020, 2 patients)
[Tier 5: Case reports]   ---> Oral JAK Inhibitors: baricitinib (Workman 2023), upadacitinib (Tolete 2025)

A treatment sitting low on this ladder is not necessarily ineffective — it is unproven. The distinction matters when a clinic offers you an expensive off-label protocol and describes it as "proven."

1. Topical 10% Metformin Compounded Cream

• Evidence Tier: Small Case Series (Araoye et al., 2020, PMID 32016152).
• Clinical Findings: Two patients with recalcitrant CCCA treated with topical 10% metformin liposomal cream demonstrated visible scalp hair regrowth at 6 months and 4 months, respectively.
• Mechanism: Metformin activates AMPK, downregulating TGF-$\beta 1$ signaling and suppressing myofibroblast differentiation to inhibit follicular scarring.

2. Oral JAK Inhibitors (Baricitinib & Upadacitinib)

• Evidence Tier: Individual case reports. Workman and Kindred (JAAD Case Rep, 2023;39:109-111) reported a 42-year-old Black woman with biopsy-confirmed CCCA whose symptoms resolved within one month and who showed regrowth in the medial parietal scalp after two months on baricitinib 4 mg daily — added on top of ongoing intralesional triamcinolone, not as monotherapy. Tolete et al. (JAAD Case Rep, 2025) subsequently reported the first case of recalcitrant CCCA treated with upadacitinib.
• Mechanism: JAK inhibition interrupts STAT3 signaling, which Roche et al. (2023) showed is activated in the perifollicular lymphocytes of CCCA patients — a rare instance where the mechanistic rationale in CCCA is directly supported by human tissue data.
• Reality check: These are two published patients. Oral JAK inhibitors carry boxed warnings covering serious infection, mortality, malignancy, major adverse cardiovascular events, and thrombosis. That risk profile against a two-case evidence base is a genuine trade-off, not a formality.

3. Low-Level Light Therapy (LLLT / Laser Caps)

• Evidence Tier: Interventional cohort study (Larrondo, Swain, Palmer, McMichael et al., J Am Acad Dermatol. 2026;94(1):341-342, PMID 40976525) — published as a short research letter, so the full protocol and effect sizes are not available in the abstract record.
• Clinical Findings: Photobiomodulation was investigated as a novel adjunctive treatment for CCCA. Because the report is a brief letter, treat the specific device parameters and magnitude of benefit as not yet independently verifiable.
• Context: LLLT devices carry FDA 510(k) clearance for androgenetic alopecia (as detailed in our guide to FDA-cleared laser caps). Clearance for pattern hair loss says nothing about CCCA; use in scarring alopecia is off-label and adjunctive at best, and it is not a substitute for anti-inflammatory therapy.

---

7. Camouflage and Surgical Options: Transplants & Scalp Micropigmentation

When CCCA has reached the burnt-out stage and scarring is fixed, medical therapies can no longer restore density. Patients often consider restorative or cosmetic camouflage procedures.

Hair Transplantation (FUE / FUT) in CCCA

Surgical hair transplantation in scarring alopecia carries unique risks compared to standard pattern baldness procedures:

1. Strict Quiescence Requirement: The scalp must demonstrate zero clinical or histological inflammation for at least 12 to 24 consecutive months before surgery. Transplanting into an actively inflamed scalp triggers graft destruction.
2. Reduced Graft Survival: Fibrotic tissue has diminished vascularity compared to healthy dermis. Graft survival rates in CCCA scalps are lower than in non-scarring alopecia.
3. Risk of Reactivation: Surgical trauma can occasionally trigger a reactivation of the inflammatory cascade.

Patients evaluating surgical options should review our comprehensive guide on FUE vs FUT hair transplantation for procedural details and donor-management strategies.

Scalp Micropigmentation (SMP)

For patients with extensive burnt-out scarring who are not candidates for surgery, scalp micropigmentation offers an effective optical camouflage. SMP deposits specialized pigments into the upper dermis to mimic shaved hair follicles or reduce visual contrast between scalp and hair.

• Safety Protocol: International Society of Hair Restoration Surgery (ISHRS) guidelines advise that scalps with scarring alopecia must be completely stable and disease-free for 2 to 3 years prior to undergoing SMP.
• Pigment Selection: Carbon-only medical pigments are strongly preferred over multi-color tattoo inks to avoid pigment oxidation and allergic reactions.
• Detailed Resource: For an in-depth breakdown of pricing, fading timelines, and FDA regulatory considerations, read our guide on scalp micropigmentation cost, fading, and safety.

---

Frequently Asked Questions

Can CCCA be cured permanently?

No. There is currently no permanent cure for CCCA. However, prompt medical treatment can successfully arrest disease progression, eliminate scalp discomfort, and preserve remaining hair indefinitely.

How is CCCA diagnosed—do I really need a scalp biopsy?

While an experienced dermatologist can strongly suspect CCCA based on trichoscopy and clinical pattern, a 4-mm punch scalp biopsy is the gold standard for definitive diagnosis. Biopsy confirms active scarring, measures inflammatory depth, and rules out mimicking conditions.

Can I keep relaxing or braiding my hair if I have CCCA?

Heavy tension styles (tight box braids, heavy weaves, tight cornrows) should be permanently avoided because mechanical stress accelerates destruction of compromised follicles. Discontinuing chemical relaxers is ideal; if maintained, application intervals must be extended to at least 10–12 weeks, with strict scalp-protection precautions.

Does topical minoxidil alone work for CCCA?

No. Minoxidil stimulates hair growth but possesses no anti-inflammatory or anti-fibrotic properties. Using minoxidil alone without anti-inflammatory agents (such as corticosteroids or doxycycline) allows the underlying destruction of hair follicles to continue unabated.

Is CCCA hereditary—should my daughters be evaluated?

Because PADI3 gene variants are inherited in an autosomal dominant pattern with variable penetrance, female first-degree relatives have an increased risk. Daughters and sisters should avoid high-tension hairstyles and undergo early dermatologic evaluation if scalp itching or crown thinning develops.

How long before I know whether CCCA treatment is working?

Initial stabilization of scalp symptoms (itching, pain, burning) typically occurs within 4 to 8 weeks. Halting of hair loss expansion and visual density evaluation requires 6 to 12 months of consistent medical therapy.

---

Sources

1. StatPearls — Central Centrifugal Cicatricial Alopecia (NBK559187). Gabros S, Sathe N, Masood S. Updated March 13, 2024. ncbi.nlm.nih.gov/books/NBK559187/
2. American Academy of Dermatology (AAD) — Central Centrifugal Cicatricial Alopecia: Overview and Treatment. aad.org/public/diseases/hair-loss/types/ccca
3. New England Journal of Medicine — Variant PADI3 in Central Centrifugal Cicatricial Alopecia. Malki L, Sarig O, Romano MT, et al. N Engl J Med. 2019;380(9):833-841. PMID: 30763140
4. Archives of Dermatology — Medical and environmental risk factors for the development of central centrifugal cicatricial alopecia: a population study. Kyei A, Bergfeld WF, Piliang M, Summers P. Arch Dermatol. 2011;147(8):909-914. PMID: 21482861
5. Journal of the American Academy of Dermatology — No association of central centrifugal cicatricial alopecia with type 2 diabetes and hypertension: A retrospective case-control study. Ong MM, Li W, Vu KV, Lipner SR. J Am Acad Dermatol. 2026;94(5):1525-1527. PMID: 41547373
6. Journal of the American Academy of Dermatology — Fibroproliferative genes are preferentially expressed in central centrifugal cicatricial alopecia. Aguh C, Dina Y, Talbot CC Jr, Garza L. J Am Acad Dermatol. 2018;79(5):904-912.e1. PMID: 29913259
7. JAAD Case Reports — Hair regrowth in 2 patients with recalcitrant central centrifugal cicatricial alopecia after use of topical metformin. Araoye EF, Thomas JAL, Aguh CU. JAAD Case Rep. 2020;6(2):106-108. PMID: 32016152
8. Journal of Investigative Dermatology — Pathogenic variants affecting peptidyl arginine deiminase 3 and its major substrates underlie central centrifugal cicatricial alopecia. Keller-Rosenthal N, et al. J Invest Dermatol. 2026;146(6):1596-1604.e2. PMID: 41242654
9. Journal of the American Academy of Dermatology — Low-level light therapy as a novel treatment for central centrifugal cicatricial alopecia: An interventional cohort study. Larrondo J, Swain E, Palmer V, et al. J Am Acad Dermatol. 2026;94(1):341-342. PMID: 40976525
10. JAAD International — Central centrifugal cicatricial alopecia is associated with longer time to diagnosis among scarring alopecias. Issa T, Klomhaus AM, Kasakevich C, Pickford J, Goh C. JAAD Int. 2025 Dec 5;24:335-337. PMID: 41561206
11. Journal of the American Academy of Dermatology — Treatment for central centrifugal cicatricial alopecia — Delphi consensus recommendations. J Am Acad Dermatol. 2024. sciencedirect.com/science/article/abs/pii/S0190962224003086
12. JAAD Case Reports — Hair regrowth in a patient with central centrifugal cicatricial alopecia after a 2-month trial of baricitinib. Workman K, Kindred C. JAAD Case Rep. 2023;39:109-111. jaadcasereports.org/article/S2352-5126(23)00265-5/fulltext
13. JAAD Case Reports — Upadacitinib for treatment of recalcitrant central centrifugal cicatricial alopecia. Tolete C, et al. JAAD Case Rep. 2025. pmc.ncbi.nlm.nih.gov/articles/PMC12887729
14. American Academy of Dermatology (AAD) — Central centrifugal cicatricial alopecia: diagnosis and treatment. aad.org/public/diseases/hair-loss/types/ccca/treatment